Retatrutide vs 5-Amino-1MQ
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: LY3437943, Triple G
A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Also: 5-amino-1-methylquinolinium, NNMT Inhibitor
A selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Retatrutide has stronger research evidence (Human Trials) compared to 5-Amino-1MQ (Animal Studies).
Detailed Comparison
| Attribute | Retatrutide | 5-Amino-1MQ |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Retatrutide activates three receptors: GLP-1 for appetite suppression and glucose control, GIP for enhanced insulin response and metabolic effects, and glucagon for increased energy expenditure and fat oxidation. The triple mechanism provides synergistic effects. | 5-Amino-1MQ inhibits NNMT, an enzyme that regulates NAD+ and SAM (S-adenosyl methionine) levels. By blocking NNMT, it increases NAD+ availability, enhancing mitochondrial function, promoting fat oxidation, and supporting cellular energy metabolism. It does not affect appetite or food intake. |
| Common Dosing | 4-12 mg weekly Once weekly, same day each week | 50-75 mg daily Once daily, morning |
| Administration | Subcutaneous injection weekly | Subcutaneous injection or oral |
| Typical Duration | Long-term use expected | 4-6 weeks (cycling recommended) |
| Best Time to Take | Morning, same day each week | Morning, fasted |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase 3 TRIUMPH-4 trial (Dec 2025) showed 28.7% weight loss at 68 weeks, with average loss of 71 lbs. Also showed significant osteoarthritis pain relief, reduced cardiovascular risk markers, and 14 mmHg blood pressure reduction. Seven more Phase 3 readouts expected in 2026. NDA submission expected late 2025/early 2026. | Mouse studies showed over 30% decrease in adipocyte size and 40% decrease in adipocyte volume. Treated mice had 30% lower total cholesterol. No significant impact on food intake or adverse effects observed. Human clinical data remains limited. |
Frequently Asked Questions: Retatrutide vs 5-Amino-1MQ
What is the difference between Retatrutide and 5-Amino-1MQ?
Retatrutide is a weight loss peptide that a triple agonist targeting glp-1, gip, and glucagon receptors. phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. expected fda approval late 2026 to early 2027. 5-Amino-1MQ is a weight loss peptide that a selective nnmt (nicotinamide n-methyltransferase) inhibitor that enhances cellular energy metabolism. not a peptide but a small molecule research compound commonly used alongside peptides for fat loss and metabolic support. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Retatrutide or 5-Amino-1MQ?
Neither is universally "better" - the choice depends on your specific goals. Retatrutide is typically used for weight loss purposes, while 5-Amino-1MQ is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Retatrutide and 5-Amino-1MQ be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Retatrutide and 5-Amino-1MQ together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Retatrutide and 5-Amino-1MQ is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.